公开(公告)号：WO2013121184A1

公开(公告)日：2013-08-22

申请号：PCT/GB2013/050311

申请日：2013-02-12

Applicant: DIURNAL LIMITED

Inventor： HUATAN, Hiep ,  ROSS, Richard ,  WHITAKER, Martin

IPC: A61K9/50 ,  A61K31/573

CPC classification number: A61K9/5026 ,  A61K9/5078 ,  A61K31/573

Abstract: The disclosure relates to a pharmaceutical formulation comprising hydrocortisone and its use in the treatment of conditions that would benefit from a delayed release of hydrocortisone, in particular conditions such as adrenal insufficiency, inflammatory conditions and depression.

Abstract translation: 本公开涉及包含氢化可的松的药物制剂及其用于治疗可受益于氢化可的松的延迟释放，特别是诸如肾上腺功能不全，炎性病症和抑郁症的病症的病症。

公开(公告)号：WO2021156043A1

公开(公告)日：2021-08-12

申请号：PCT/EP2021/050930

申请日：2021-01-18

Applicant: DIURNAL LIMITED

Inventor： WHITAKER, Martin ,  PORTER, John ,  ROSS, Richard ,  JONES, Stewart ,  COCKS, Elizabeth

IPC: A61K31/568 ,  A61K47/44 ,  A61K47/10 ,  A61K47/14 ,  A61P5/26 ,  A61K9/00 ,  A61K9/48

Abstract: A pharmaceutical composition for adapted for oral administration comprising at least 10 % w/w native testosterone, at least 36% w/w sesame oil, at least 28% w/w propylene glycol monolaurate, at least 9 % w/w ethanol and at least 14 % w/w benzyl alcohol. A dosage regimen for use in a human subject comprising administering at least a first and a second pharmaceutical compositions wherein, the first composition comprises between 2.5-7.5 % w/w native testosterone, sesame oil, propylene glycol monolaurate, ethanol and benzyl alcohol; and the second composition comprises at least 9% w/w native testosterone, sesame oil, propylene glycol monolaurate, ethanol and benzyl alcohol; wherein said first and second compositions are administered orally at least once in a 24- hour period to said human subject to normalise serum testosterone. A process to produce a composition comprising native testosterone comprising i) forming a homogeneous preparation comprising sesame oil, propylene glycol monolaurate, benzyl alcohol and ethanol; ii) adding native testosterone at a concentration of about 13% w/w to said homogeneous preparation to form a combined testosterone preparation; and iii) mixing the combined preparation to dissolve testosterone to form a substantially clear preparation.

公开(公告)号：WO2014184525A1

公开(公告)日：2014-11-20

申请号：PCT/GB2014/051442

申请日：2014-05-12

Applicant: DIURNAL LIMITED

Inventor： HUATAN, Hiep ,  ROSS, Richard ,  WHITAKER, Martin ,  POELLINGER, Norbert ,  GRAVE, Annette

IPC: A61K9/50 ,  A61K31/57

CPC classification number: A61K9/5078 ,  A61K9/0053 ,  A61K9/5015 ,  A61K9/5042 ,  A61K9/5047 ,  A61K31/573

Abstract: The disclosure relates to pharmaceutical compositions useful in the treatment of adrenal insufficiency in paediatric or elderly subjects.

Abstract translation: 本公开涉及可用于治疗儿科或老年受试者的肾上腺功能不全的药物组合物。

公开(公告)号：WO2013072707A1

公开(公告)日：2013-05-23

申请号：PCT/GB2012/052864

申请日：2012-11-19

Applicant: DIURNAL LIMITED

Inventor： HUATAN, Hiep ,  ROSS, Richard ,  WHITAKER, Martin

IPC: A61K9/50 ,  A61K31/573

CPC classification number: A61K31/573 ,  A23L2/52 ,  A23L33/10 ,  A23V2002/00 ,  A61K9/0053 ,  A61K9/0095 ,  A61K9/5026 ,  A61K9/5042 ,  A61K9/5047 ,  A61K9/5078 ,  A61K9/5089

Abstract: The disclosure relates to the treatment of adrenal insufficiency with particular but not limiting application to paediatric treatment regimens, the treatment of the elderly and non-human animals.

Abstract translation: 本公开涉及治疗肾上腺功能不全，特别但不限于儿科治疗方案，老年人和非人类动物的治疗。